Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Craney A, Petrik D, Suhku A, Qiu Y, Racine-Brzostek S, Rennert H, et al. Performance Evaluation of the MatMaCorp COVID-19 2SF Assay for the Detection of SARS-CoV-2 from Nasopharyngeal Swabs. Microbiol Spectr. 2021;9(1):e0008321.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res. 2021;81(7):1704-1718.

Rosenbaum JN, Berry AB, Church AJ, Crooks K, Gagan JR, López-Terrada D, et al. A Curriculum for Genomic Education of Molecular Genetic Pathology Fellows: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2021;23(10):1218-1240.

Nickeleit V, Singh HK, Dadhania D, Cornea V, El-Husseini A, Castellanos A, et al. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era. Am J Transplant. 2021;21(2):669-680.

McIntire PJ, Elsoukkary SS, Robinson BD, Siddiqui MT. High-grade urothelial carcinoma in urine cytology: different spaces - different faces, highlighting morphologic variance. J Am Soc Cytopathol. 2021;10(1):36-40.

Yang HS, LaFrance DR, Hao Y. Elemental Testing Using Inductively Coupled Plasma Mass Spectrometry in Clinical Laboratories. Am J Clin Pathol. 2021;156(2):167-175.

Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, et al. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer. Thyroid. 2021.

Patel A, Hoda RS, Hoda SA. Papillary Breast Tumors: Continuing Controversies and Commentary on WHO's 2019 Criteria and Classification. Int J Surg Pathol. 2021:10668969211035843.

Nagirnaja L, Mørup N, Nielsen JE, Stakaitis R, Golubickaite I, Oud MS, et al. Variant , Defective piRNA Processing, and Azoospermia. N Engl J Med. 2021;385(8):707-719.

Tabbo F, Guerrera F, van den Berg A, Gaudiano M, Maletta F, Bessone L, et al. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. Eur J Cancer. 2021;144:17-30.